etanercept, Enbrel (cont.)
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
Some reported associated conditions may or may not be related to etanercept.
Other important side effects include:
For this reason, etanercept is not recommended for persons with preexisting disease of the central nervous system (brain and/or spinal cord) or for those with multiple sclerosis, myelitis, or optic neuritis. Additionally, rare cases of seriously low blood counts (pancytopenia) have been reported in patients using etanercept. New cases or worsening of congestive heart failure may occur.
GENERIC AVAILABLE: No
PREPARATIONS: 25 mg multiple use vial; 25 or 50 mg prefilled syringe; 50 mg prefilled autoinjector.
STORAGE: Sterile powder and pre-filled syringes should be refrigerated at 2 C to 8 C (36 F to 46 F). Reconstituted solutions made from the powder should be used as soon as possible but may be stored in the vial at 2 C - 8 C (36 F - 46 F) for 14 days.
PRESCRIBED FOR: Etanercept is used as primary treatment to reduce the pain, swelling, and tenderness of joints resulting from moderate to severe rheumatoid arthritis in adults. It also may be used when rheumatoid arthritis has not adequately responded to other drugs (called disease-modifying drugs for rheumatoid arthritis). For example, etanercept can be used in combination with methotrexate (Rheumatrex, Trexall) in patients who do not respond adequately to methotrexate alone.
Etanercept also is used to reduce the signs and symptoms of moderately to severely active, polyarticular-course, juvenile rheumatoid arthritis in children who have had an inadequate response to one or more disease-modifying drugs.
Etanercept is approved for the treatment of ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. It can prevent the progressive destruction of joints and improve physical function with psoriatic arthritis.
Medically Reviewed by a Doctor on 9/10/2015
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index